Evidence map›Paper›PMID 19569178›Full record

ArticleInternational journal of cancer2009

Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.

Rosemary E Zuna, William E Moore, Rebecca P Shanesmith, S Terence Dunn, Sophia S Wang, Mark Schiffman, Gregory L Blakey, Travis Teel

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Article
  13. Article
  14. Article
  15. The frequency of high-risk human papillomavirus types, HPV16 lineages, and their relationship with p16Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rosemary E ZunaDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
William E Moore
Rebecca P Shanesmith
S Terence Dunn
Sophia S Wang
Mark Schiffman
Gregory L Blakey
Travis Teel
University of Oklahoma Health Sciences Center · USNational Cancer Institute · USNational Institutes of Health · US

Funding

Human papillomavirus (HPV) infection and cervical and anal cancersZIACP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI WENTZENSEN, NICOLAS · 2009 to 2025
$17.3M
HPV Type and Biological Potential of Cervical LesionsR03CA117523 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZUNA, ROSEMARY E · 2005 to 2006
$145k
Intramural NIH HHSNCI NIH HHS N02 CP031102NCI NIH HHS R03 CA117523NCI NIH HHS R03-CA117523
6 · The paper itself

Abstract

It has been suggested that DNA sequence variants of HPV16 contribute to differences in the behavior of individual cervical lesions. To address this question, we have analyzed the association of HPV16 variants with diagnostic severity in 354 HPV16-positive Oklahoman women. HPV16 variant status was determined by PCR amplification and DNA sequencing of the E6 open reading frame. European sequences were identified in 86% of samples and 14% were non-European. Of the 51 non-European cases, 61% were Asian-American, 23% African and 16% were Native American variants. European prototype and related variants were present in comparable numbers (43% each) but the relative proportion of each differed with diagnostic category. In general, the proportion of European variants and non-European variants increased with diagnostic severity while the European prototype decreased. When adjusted for age and race (white, black or Hispanic), the increased risk for carcinoma/severe dysplasia for non-European variants was statistically significant with an odds ratio of 3.8 (1.3-10.7). However, the analogous comparison for the European variants, although also showing increased association with carcinoma/severe dysplasia, did not reach statistical significance (OR = 1.6 (95% CI 0.7-3.6). Overall, HPV16 European sequences (both prototype and related variants), were predominant in Oklahoman women including those with cancers. This suggests that while there appear to be differences among the HPV16-variant categories in risk for progression to invasive cancer, all variant categories are associated with the development of invasive cancer.

Indexed as

Genetic VariationAdolescentAdultAgedAged, 80 and overCytodiagnosisDNA, NeoplasmDNA, ViralFemaleHuman papillomavirus 16Human papillomavirus 18HumansMiddle AgedOncogene Proteins, ViralPapillomavirus InfectionsPolymerase Chain ReactionDNA, NeoplasmDNA, ViralE6 protein, Human papillomavirus type 16Oncogene Proteins, ViralRepressor Proteins

Identifiers

PMID19569178
PMCPMC2757470
OpenAlexW2026598187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.